Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2Endocrine 2Head & Neck 1CNS 1

Conditions

Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Metastatic Neuroendocrine Prostate Cancer 1Adenocarcinoma, Follicular 1

Interventions

Specimen Handling 13Magnetic Resonance Spectroscopy 13lutetium Lu 177 dotatate 10cabozantinib 6Nivolumab 5X-Rays 4Ipilimumab 4Cisplatin 4pembrolizumab 3olaparib 3fludarabine 3Phantoms, Imaging 3Everolimus 3Etoposide 3Cyclophosphamide 3Carboplatin 3CTLA-4 Antigen 3gallium Ga 68 dotatate 2fluorodopa F 18 2aldesleukin 2Temozolomide 2Lutetium-177 2Lutetium 2Irinotecan 2Fluorodeoxyglucose F18 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2trametinib 1tipifarnib 1sodium thiosulfate 1selpercatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
gallium Ga 68 dotatate × Endocrine × 30 days × Clear all
NCT06379217 2026-06-03

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Novartis

Phase 1 Active not recruiting
31 enrolled
EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

NCT00001160 2026-05-12

Studies on Tumors of the Thyroid

National Institutes of Health Clinical Center (CC)

Recruiting
2,500 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡